2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Treatment Considerations, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Elderly, Animal Model
PAPER

3825 SF3B1 mutations alter human hematopoietic stem cell interactions with the niche

Laura Baquero Galvis, BS, Suhita Ray, PhD2, Ioanna Mosialou, Assistant Professor3, Stavroula Kousteni, PhD4, Martina Sarchi, MD, PhD5, Sergei Doulatov, PhD6
1 Columbia University, New York, New York, United States, University of Washington, Seattle, Washington, United States
2 Columbia University, New York, New York, United States
3 Columbia University, New York, New York, United States
4 Columbia University, New York, New York, United States
5 IRCCS San Matteo Hospital Foundation, Pavia, Italy, University of Pavia, Pavia, Italy
6 Columbia University, New York, New York, United States

Myelodysplastic syndromes (MDS) are clonal hematologic malignancies arising from the oncogenic transformation of hematopoietic stem cells (HSCs) harboring driver mutations. Core splicing factor SF3B1 mutations are found in up to 30% of MDS patients and ~80% of MDS with ring sideroblasts. SF3B1 is a component of the SF3b complex that binds the intronic branchpoint on precursor mRNAs to facilitate 3’ splice site selection and proper intron removal. Change-of-function hotspot mutations in SF3B1 alter branchpoint recognition, leading to the selection of aberrant 3’ splice sites and target gene mis-splicing. SF3B1 mutations that occur in HSCs before the onset of MDS confer a clonal advantage, and splicing changes induced by these mutations promote MDS development and progression. Previous studies have focused on characterizing mutant SF3B1 mis-splicing in erythropoiesis; however, it remains unclear how mis-splicing disrupts human HSC function.

To assess the role of mutant SF3B1 in primary human HSCs, we have used precise CRISPR/Cas9 editing and AAV6-mediated homologous recombination to engineer the SF3B1 K700E mutation or K700K control and a BFP fluorescent reporter in human cord-blood-derived (CB) CD34+ cells (Sarchi et al. 2024). Consistent with previous reports, SF3B1 K700E mutant HSCs proliferated poorly in liquid culture, with reduced expansion (~50-60% of the control) and decreased immature CD34+CD133+ compartment. We next transplanted SF3B1-edited cells into NSG or NSGS immunodeficient mice via intra-femoral injections and tracked human chimerism and lineage distribution 14-16 weeks post-transplant. By contrast with in vitro culture, SF3B1 K700E and K700K controls displayed comparable engraftment across multiple independent in vivo experiments (n=16, mice), as quantified by the percentage of human CD45+BFP+ cells in the bone marrow. Control K700K cells efficiently engrafted in the injected femur and migrated to non-injected bone marrow sites. Surprisingly, SF3B1 K700E cells preferentially remained at the site of injection with reduced migration to non-injected sites. These findings demonstrate that SF3B1 K700E human HSCs are maintained in vivo and show reduced migration to other bones, suggesting altered interactions with the bone marrow microenvironment.

Gene expression analysis of CD34+ HSPCs from MDS patients revealed upregulation of pathways mediating niche interaction in SF3B1-mutant HSPCs (n=16) compared to SF3B1 WT (n=32) or normal CD34+ cells (n=3). To model the interactions between SF3B1-mutant HSCs and the microenvironment, we performed co-culture with bone marrow-derived stromal cells from healthy individuals. Interestingly, SF3B1-mutant HSPCs were physically more adherent to the stroma compared to controls. Moreover, adherent mutant cells had a higher frequency of CD34+CD133+CD38- phenotypic HSCs compared to controls. These findings show that SF3B1-mutant HSPCs exhibit enhanced adhesion to bone marrow stromal cells, which may promote mutant HSC maintenance and expansion. In conclusion, we established an in vivo model of human SF3B1-mutant MDS and demonstrated the impact of SF3B1 mutations on interactions with the niche. Ongoing experiments are aimed at understanding the mechanisms by which stromal cells support the expansion of SF3B1-mutant clones in the bone marrow.

Laura Baquero Galvis, BS: No relevant conflicts of interest to declare.